Keywords: pharma/biotech, ipos, bayer, otc, outlook, editor, views
Pharma/biotech IPOs, and Bayer OTC outlook; Editor's views
Article | 05 July 2004
European pharmaceutical start-ups and biotechnology companies havecomplained for a while about the poor investment climate, particularly when compared with their ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
